J&J’s $2.2B Deal A Last Hurrah For Off-Label Crackdown

Law360, New York (November 4, 2013, 7:46 PM EST) -- Johnson & Johnson's $2.2 billion deal Monday to end a vast False Claims Act investigation will probably be one of the last monster settlements under a long-running crusade against off-label marketing, with other drugmakers having already learned costly lessons and the federal government setting its sights on new sectors, attorneys say.

The 10-figure payout by J&J was striking not just for how many zeroes it contained, but also for how familiar such colossal penalties have become in recent years, with the who’s-who of Big Pharma repeatedly...
To view the full article, register now.